Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer.

[1]  P. Mukeňsnabl,et al.  Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. , 2009, Anticancer research.

[2]  Edward S. Kim,et al.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial , 2008, The Lancet.

[3]  Ping Yang,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[4]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[5]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[6]  F. Shepherd,et al.  Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes , 2008, Current opinion in oncology.

[7]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[8]  S. Kakar,et al.  Comparison of the Dako EGFR pharmDx Kit and Zymed EGFR Antibody for Assessment of EGFR Status in Colorectal Adenocarcinoma , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[9]  Kyle Porter,et al.  Semi‐automated imaging system to quantitate Her‐2/neu membrane receptor immunoreactivity in human breast cancer , 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[10]  F. Penault-Llorca,et al.  Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment? , 2006, Oncology reports.

[11]  F. Cappuzzo,et al.  Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Varella‐Garcia,et al.  Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay , 2006, Diagnostic pathology.

[13]  Ming-Sound Tsao,et al.  K-ras mutations in non-small-cell lung carcinoma: a review. , 2006, Clinical lung cancer.

[14]  A. Italiano,et al.  Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Tsao,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. , 2006, Clinical lung cancer.

[16]  F. Cappuzzo,et al.  Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[18]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[19]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[20]  G. Giaccone.  HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Hiroyuki Sakurai,et al.  Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas , 2005, Cancer.

[22]  J. Rigas,et al.  Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Scagliotti,et al.  The Biology of Epidermal Growth Factor Receptor in Lung Cancer , 2004, Clinical Cancer Research.

[24]  A. Santoro,et al.  Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer , 2004, British Journal of Cancer.

[25]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[26]  Vincent Ninane,et al.  Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. , 2004, Lung cancer.

[27]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[28]  J. Dancey.  Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow. , 2004, Cancer cell.

[29]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Dmitrovsky,et al.  Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  L. Crinò,et al.  Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. , 2009, Lung cancer.

[32]  T. Mukohara,et al.  Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC. , 2004, Anticancer research.